Syreeta Tilghman to Breast Neoplasms
This is a "connection" page, showing publications Syreeta Tilghman has written about Breast Neoplasms.
Connection Strength
2.756
-
Patel JR, Banjara B, Ohemeng A, Davidson AM, Bou? SM, Burow ME, Tilghman SL. Novel Therapeutic Combination Targets the Growth of Letrozole-Resistant Breast Cancer through Decreased Cyclin B1. Nutrients. 2023 Mar 28; 15(7).
Score: 0.406
-
Walker RR, Patel JR, Gupta A, Davidson AM, Williams CC, Payton-Stewart F, Bou? SM, Burow ME, Khupse R, Tilghman SL. Glyceollins Trigger Anti-Proliferative Effects in Hormone-Dependent Aromatase-Inhibitor-Resistant Breast Cancer Cells through the Induction of Apoptosis. Int J Mol Sci. 2022 Mar 07; 23(5).
Score: 0.377
-
Walker RR, Gallegos KM, Bratton MR, Lemieux KP, Zhang K, Wang G, Davidson AM, Tilghman SL. Acquisition of Letrozole Resistance Through Activation of the p38/MAPK Signaling Cascade. Anticancer Res. 2021 Feb; 41(2):583-599.
Score: 0.350
-
Gupta A, Gupta G, Mehta RR, Ivancic DZ, Walker RR, Patel JR, Gallegos KM, Davidson AM, Khan SA, Mehta RG, Tilghman SL. A novel and cost-effective ex vivo orthotopic model for the study of human breast cancer in mouse mammary gland organ culture. Biol Open. 2020 05 29; 9(5).
Score: 0.334
-
Carriere PP, Llopis SD, Naiki AC, Nguyen G, Phan T, Nguyen MM, Preyan LC, Yearby L, Pratt J, Burks H, Davenport IR, Nguyen TA, Parker-Lemieux K, Payton-Stewart F, Williams CC, Bou? SM, Burow ME, Collins-Burow B, Hilliard A, Davidson AM, Tilghman SL. Glyceollin I Reverses Epithelial to Mesenchymal Transition in Letrozole Resistant Breast Cancer through ZEB1. Int J Environ Res Public Health. 2015 Dec 22; 13(1):ijerph13010010.
Score: 0.245
-
Tilghman SL, Townley I, Zhong Q, Carriere PP, Zou J, Llopis SD, Preyan LC, Williams CC, Skripnikova E, Bratton MR, Zhang Q, Wang G. Proteomic signatures of acquired letrozole resistance in breast cancer: suppressed estrogen signaling and increased cell motility and invasiveness. Mol Cell Proteomics. 2013 Sep; 12(9):2440-55.
Score: 0.205
-
Tilghman SL, Rhodes LV, Bratton MR, Carriere P, Preyan LC, Boue SM, Vasaitis TS, McLachlan JA, Burow ME. Phytoalexins, miRNAs and breast cancer: a review of phytochemical-mediated miRNA regulation in breast cancer. J Health Care Poor Underserved. 2013 Feb; 24(1 Suppl):36-46.
Score: 0.201
-
Tilghman SL, Bratton MR, Segar HC, Martin EC, Rhodes LV, Li M, McLachlan JA, Wiese TE, Nephew KP, Burow ME. Endocrine disruptor regulation of microRNA expression in breast carcinoma cells. PLoS One. 2012; 7(3):e32754.
Score: 0.189
-
Ferguson DT, Taka E, Tilghman SL, Womble T, Redmond BV, Gedeon S, Flores-Rozas H, Reed SL, Soliman KFA, Kanga KJW, Darling-Reed SF. The Anticancer Effects of the Garlic Organosulfide Diallyl Trisulfide through the Attenuation of B[a]P-Induced Oxidative Stress, AhR Expression, and DNA Damage in Human Premalignant Breast Epithelial (MCF-10AT1) Cells. Int J Mol Sci. 2024 Jan 11; 25(2).
Score: 0.107
-
Williams MD, Nguyen T, Carriere PP, Tilghman SL, Williams C. Protein Kinase CK2 Expression Predicts Relapse Survival in ERa Dependent Breast Cancer, and Modulates ERa Expression in Vitro. Int J Environ Res Public Health. 2015 Dec 22; 13(1):ijerph13010036.
Score: 0.061
-
Payton-Stewart F, Tilghman SL, Williams LG, Winfield LL. Benzimidazoles diminish ERE transcriptional activity and cell growth in breast cancer cells. Biochem Biophys Res Commun. 2014 Aug 08; 450(4):1358-62.
Score: 0.055
-
Johnson KP, Yearby LA, Stoute D, Burow ME, Rhodes LV, Gray M, Carriere P, Tilghman SL, McLachlan JA, Ochieng J. In vitro and in vivo evaluation of novel anticancer agents in triple negative breast cancer models. J Health Care Poor Underserved. 2013 Feb; 24(1 Suppl):104-11.
Score: 0.050
-
Martin EC, Bratton MR, Zhu Y, Rhodes LV, Tilghman SL, Collins-Burow BM, Burow ME. Insulin-like growth factor-1 signaling regulates miRNA expression in MCF-7 breast cancer cell line. PLoS One. 2012; 7(11):e49067.
Score: 0.050
-
Rhodes LV, Bratton MR, Zhu Y, Tilghman SL, Muir SE, Salvo VA, Tate CR, Elliott S, Nephew KP, Collins-Burow BM, Burow ME. Effects of SDF-1-CXCR4 signaling on microRNA expression and tumorigenesis in estrogen receptor-alpha (ER-a)-positive breast cancer cells. Exp Cell Res. 2011 Nov 01; 317(18):2573-81.
Score: 0.045
-
Rhodes LV, Short SP, Neel NF, Salvo VA, Zhu Y, Elliott S, Wei Y, Yu D, Sun M, Muir SE, Fonseca JP, Bratton MR, Segar C, Tilghman SL, Sobolik-Delmaire T, Horton LW, Zaja-Milatovic S, Collins-Burow BM, Wadsworth S, Beckman BS, Wood CE, Fuqua SA, Nephew KP, Dent P, Worthylake RA, Curiel TJ, Hung MC, Richmond A, Burow ME. Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. Cancer Res. 2011 Jan 15; 71(2):603-13.
Score: 0.043
-
Macedo LF, Guo Z, Tilghman SL, Sabnis GJ, Qiu Y, Brodie A. Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole. Cancer Res. 2006 Aug 01; 66(15):7775-82.
Score: 0.032
-
Long BJ, Tilghman SL, Yue W, Thiantanawat A, Grigoryev DN, Brodie AM. The steroidal antiestrogen ICI 182,780 is an inhibitor of cellular aromatase activity. J Steroid Biochem Mol Biol. 1998 Nov; 67(4):293-304.
Score: 0.005